Fuzeon Lyophilisate For Solution For Injection 90Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Fuzeon: Lyophilisate for solution for injection (90mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

ENFUVIRTIDE (en FYOO vir tide) is an antiretroviral drug. It is used with other medicines to treat HIV. This medicine is not a cure for HIV. It will not stop the spread of HIV to others.

In-Depth Information

Fuzeon 90mg Convenience Kit

NDC: 000040381
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Human Immunodeficiency Virus (HIV) Infection

Sometimes used for but not FDA approved for the following conditions:
Human Immunodeficiency Virus (HIV) Prophylaxis

Storage Information
Store reconstituted product in refrigerator (36 to 46 degrees F) and administer within 24 hours
Store in original container
Discard product if it contains particulate matter, is cloudy, or discolored
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Fuzeon 90mg Convenience Kit

Reported Side Effects for Fuzeon 90mg Convenience Kit

Blood In The Urine Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Fluid Retention Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Vomiting Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Chills Incidence:
<1.0%*
Severity: MILD
Onset: RAPID
Glomerulonephritis Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Skin Rash Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Acute Lung Injury Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Shortness Of Breath Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Low Blood Pressure Incidence:
<1.0%*
Severity: MODERATE
Onset: RAPID
Guillain-Barre Syndrome Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Fever Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Elevated Hepatic Enzymes Incidence:
1.2-4.1%*
Severity: MODERATE
Onset: DELAYED
Eosinophilia Incidence:
1.8-9.1%*
Severity: MODERATE
Onset: DELAYED
Conjunctivitis Incidence:
2.0%*
Severity: MODERATE
Onset: DELAYED
Dry Mouth Incidence:
2.1%*
Severity: MILD
Onset: EARLY
Decreased Appetite Incidence:
2.3%*
Severity: MILD
Onset: DELAYED
Flu Incidence:
2.4%*
Severity: MILD
Onset: DELAYED
Inflamed Hair Follicles Incidence:
2.4%*
Severity: MILD
Onset: DELAYED
Muscle Pain Incidence:
2.7%*
Severity: MILD
Onset: EARLY
Infection Incidence:
2.7-10.7%*
Severity: MILD
Onset: DELAYED
Inflamed Pancreas Incidence:
3.0%*
Severity: SEVERE
Onset: DELAYED
Cough Incidence:
3.9%*
Severity: MILD
Onset: DELAYED
Stomach Pain Incidence:
3.9%*
Severity: MILD
Onset: EARLY
Sinus Infection Incidence:
6.0%*
Severity: MILD
Onset: DELAYED
Weight Loss Incidence:
6.6%*
Severity: MILD
Onset: DELAYED
Tired Incidence:
20.2%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
22.8%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
31.7%*
Severity: MILD
Onset: EARLY
Bruise Incidence:
52.0%*
Severity: MILD
Onset: DELAYED
Itching Incidence:
65.0%*
Severity: MILD
Onset: RAPID
Skin Redness Incidence:
91.0%*
Severity: MODERATE
Onset: EARLY
Injection Site Reaction Incidence:
98.0%*
Severity: MILD
Onset: RAPID
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

SECOND Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

THIRD Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Fuzeon

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5